Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa sporozoite challenge study of adjuvanted R21 malaria vaccine in healthy UK adults
2018-004391-34Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of R21/Matrix-M in Falciparum malaria (PF) and Malaria, sponsored by University of Oxford. Primary endpoints: Safety and tolerability of adjuvanted R21 and Protective efficacy against Plasmodium falciparum parasitemia. Status: unknown.
02
Drugs
R21/Matrix-M
03
Conditions
Falciparum malaria (PF)Malaria
Beyond the preview
Go deeper on 2018-004391-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004391-34.